搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
5 小时
The week in pharma: action, reaction and insight – week to September 2024
Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...
The Pharma Letter
1 天
Ipsen’s Iqirvo approved in Europe
The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...
The Pharma Letter
1 天
FluMist approved for self-administration in the USA
On Friday, the US Food and Drug Administration approved UK pharma major AstraZeneca’s (LSE: AZN) FluMist for self- or ...
The Pharma Letter
2 天
Achilles Thera shifts focus to new cancer treatment avenues
Achilles Therapeutics has announced it will discontinue its tumor-infiltrating lymphocyte (TIL)-based clonal neoantigen T ...
The Pharma Letter
2 天
Wegovy label should be extended, CHMP recommends
The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...
The Pharma Letter
1 天
Trump vs Harris—who's on Big Pharma's side?
US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have ...
The Pharma Letter
2 天
Novo Nordisk’s obesity newcomer monlunabant heads into Phase IIb
Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.
The Pharma Letter
2 天
FDA approves first Niemann-Pick disease, type C treatment
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of ...
The Pharma Letter
1 天
Takeda‘s Fruzaqla wins UK approval for CRC
The UK’s MHRA has approved Takeda’s Fruzaqla (fruquintinib) for metastatic colorectal cancer (CRC) in adults who have not ...
The Pharma Letter
2 天
$268 million BARDA deal for Basilea
Basilea Pharmaceutica (SIX: BSLN) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of ...
The Pharma Letter
2 天
Phase III win for tolebrutinib in progressive multiple sclerosis
Sanofi has reported positive results from its Phase III HERCULES trial of tolebrutinib for non-relapsing secondary ...
The Pharma Letter
2 天
Latest batch of EMA’s human medicines committee recommendations
Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈